FLT3 and acute myeloid leukemia: We focused on FLT3ITD mutant cells treated with FLT3-TKI because MPI expression is higher in this AML subtype and adaptive resistance to FLT3-TKI is less well described thus necessitating a better understanding given the increasing clinical use of FLT3-TKI.